HLA-A2-restricted peripheral blood cytolytic T lymphocyte response to HPV type 16 proteins E6 and E7 from patients with neoplastic cervical lesions.

C Evans; S Bauer; T Grubert; Cosima Brucker; S Baur; K Heeg; H Wagner; G B Lipford

HLA-A2-restricted peripheral blood cytolytic T lymphocyte response to HPV type 16 proteins E6 and E7 from patients with neoplastic cervical lesions.

C Evans, S Bauer, T Grubert, Cosima Brucker (Co-Autor/-in), S Baur, K Heeg, H Wagner, G B Lipford

Publikation: Beitrag in Fachzeitschrift › Originalarbeit › Begutachtung

49 Quellenangaben (Web of Science)

Originalsprache	Englisch
Seiten (von - bis)	151-160
Fachzeitschrift	CANCER IMMUNOLOGY, IMMUNOTHERAPY : CII
Jahrgang	42
Ausgabenummer	3
Publikationsstatus	Veröffentlicht - 1996

Dieses zitieren

@article{2d450d4cd88c4ddda9feec5c1858580f,

title = "HLA-A2-restricted peripheral blood cytolytic T lymphocyte response to HPV type 16 proteins E6 and E7 from patients with neoplastic cervical lesions.",

keywords = "HUMAN PAPILLOMAVIRUS INFECTION, CARCINOMA CELL-LINES, INTRAEPITHELIAL NEOPLASIA, FUSION PROTEINS, ANTIGEN, EXPRESSION, SEQUENCES, EPITOPE, VIRUS, RISK",

author = "C Evans and S Bauer and T Grubert and Cosima Brucker and S Baur and K Heeg and H Wagner and Lipford, {G B}",

year = "1996",

language = "English",

volume = "42",

pages = "151--160",

journal = "CANCER IMMUNOLOGY, IMMUNOTHERAPY : CII",

issn = "0340-7004",

publisher = "Springer Verlag",

number = "3",

}

TY - JOUR

T1 - HLA-A2-restricted peripheral blood cytolytic T lymphocyte response to HPV type 16 proteins E6 and E7 from patients with neoplastic cervical lesions.

AU - Evans, C

AU - Bauer, S

AU - Grubert, T

AU - Brucker, Cosima

AU - Baur, S

AU - Heeg, K

AU - Wagner, H

AU - Lipford, G B

PY - 1996

Y1 - 1996

KW - HUMAN PAPILLOMAVIRUS INFECTION

KW - CARCINOMA CELL-LINES

KW - INTRAEPITHELIAL NEOPLASIA

KW - FUSION PROTEINS

KW - ANTIGEN

KW - EXPRESSION

KW - SEQUENCES

KW - EPITOPE

KW - VIRUS

KW - RISK

M3 - Original Article

C2 - 8640843

SN - 0340-7004

VL - 42

SP - 151

EP - 160

JO - CANCER IMMUNOLOGY, IMMUNOTHERAPY : CII

JF - CANCER IMMUNOLOGY, IMMUNOTHERAPY : CII

IS - 3

ER -